Shield Therapeutics Share Forecast, Price & News

GBX 45
+1.80 (+4.17 %)
(As of 04/21/2021 04:28 PM ET)
Today's Range
Now: GBX 45
50-Day Range
MA: GBX 39.86
52-Week Range
Now: GBX 45
Volume662,479 shs
Average Volume1.66 million shs
Market Capitalization£97.13 million
P/E RatioN/A
Dividend YieldN/A
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Shield Therapeutics logo

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Year FoundedN/A



Sales & Book Value

Annual Sales£9.21 million
Cash FlowGBX 5.36 per share
Book ValueGBX 30.30 per share



Market Cap£97.13 million
Next Earnings Date5/17/2021 (Estimated)


Shield Therapeutics (LON:STX) Stock Price Up 5.6%
April 17, 2021 |  americanbankingnews.com
Shield Therapeutics : Investor Presentation
March 4, 2021 |  markets.businessinsider.com
See More Headlines


Overall MarketRank

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
GBX 45
+1.80 (+4.17 %)
(As of 04/21/2021 04:28 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STX News and Ratings via Email

Sign-up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Shield Therapeutics (LON:STX) Frequently Asked Questions

Is Shield Therapeutics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Shield Therapeutics stock.
View analyst ratings for Shield Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Shield Therapeutics?

Wall Street analysts have given Shield Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Shield Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Shield Therapeutics' next earnings date?

Shield Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 17th 2021.
View our earnings forecast for Shield Therapeutics

How has Shield Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Shield Therapeutics' stock was trading at GBX 121.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, STX stock has decreased by 63.0% and is now trading at GBX 45.
View which stocks have been most impacted by COVID-19

Who are Shield Therapeutics' key executives?

Shield Therapeutics' management team includes the following people:
  • Mr. Timothy William Watts, CEO & Director (Age 63)
  • Mr. Hans-Peter Rudolf, Chief Financial Officer
  • Fleur Wood, Director of Investor Relations
  • Ms. Lucy Huntington-Bailey, Gen. Counsel & Company Sec.
  • Ms. Suzanne Wood, Group HR Director
  • Mr. Paul Steckler, Chief Commercial Officer
  • Ms. Carol Akinola, Head of Pharmacovigilance & Medical Information

Who are some of Shield Therapeutics' key competitors?

What other stocks do shareholders of Shield Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN), Concepta PLC (CPT.L) (CPT), Fresnillo (FRES), OptiBiotix Health (OPTI) and SkinBioTherapeutics (SBTX).

What is Shield Therapeutics' stock symbol?

Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX."

How do I buy shares of Shield Therapeutics?

Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Shield Therapeutics' stock price today?

One share of STX stock can currently be purchased for approximately GBX 45.

How much money does Shield Therapeutics make?

Shield Therapeutics has a market capitalization of £97.13 million and generates £9.21 million in revenue each year.

How many employees does Shield Therapeutics have?

Shield Therapeutics employs 20 workers across the globe.

What is Shield Therapeutics' official website?

The official website for Shield Therapeutics is www.shieldtherapeutics.com.

Where are Shield Therapeutics' headquarters?

Shield Therapeutics is headquartered at 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom.

How can I contact Shield Therapeutics?

Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500.

This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.